Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H44O3 |
| Molecular Weight | 416.6365 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]16CC[C@@H](C)CO6
InChI
InChIKey=GMBQZIIUCVWOCD-MFRNJXNGSA-N
InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3/t16-,17+,18+,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1
| Molecular Formula | C27H44O3 |
| Molecular Weight | 416.6365 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tigogenin is a saponin and acts as a natural plant steroid which induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes. This action is associated with overexpression of COX-2 correlated with overproduction of endogenous PGE2. In addition, it was found that through the inhibition of PPAR gamma and via the p38 MAPK pathway tigogenin has the potential to prevent the development of osteoporosis and the related disorders.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P37231|||Q15179 Gene ID: 5468.0 Gene Symbol: PPARG Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17363141 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells. | 2007-05-30 |
|
| Tigogenin and ursolic acid from Cestrum diurnum Linn. | 1964-04-15 |
|
| A new source for tigogenin. | 1962-04 |
|
| Steroidal sapogenins; magogenin and cacogenin and their biogenesis to chlorogenin and tigogenin. | 1947-10 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17786275
Curator's Comment: Tigogenin was more effective than hecogenin in inducing apoptosis in human Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) which was caspase dependent but poly(ADP-ribose) polymerase independent and characterized by DNA fragmentation. It was demonstrated, that tigogenin-induced apoptosis through activation of p38 without affecting the JNK and ERK pathways. Indeed, pretreatment with a p38 inhibitor decreased saponin-induced apoptosis with a significant decrease in DNA fragmentation. Furthermore, the rate of apoptosis induced by tigogenin was associated with overexpression of COX-2 correlated with overproduction of endogenous PGE2.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:29:42 GMT 2025
by
admin
on
Mon Mar 31 22:29:42 GMT 2025
|
| Record UNII |
4SMU15RR44
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
201-041-9
Created by
admin on Mon Mar 31 22:29:42 GMT 2025 , Edited by admin on Mon Mar 31 22:29:42 GMT 2025
|
PRIMARY | |||
|
DTXSID40903920
Created by
admin on Mon Mar 31 22:29:42 GMT 2025 , Edited by admin on Mon Mar 31 22:29:42 GMT 2025
|
PRIMARY | |||
|
9595
Created by
admin on Mon Mar 31 22:29:42 GMT 2025 , Edited by admin on Mon Mar 31 22:29:42 GMT 2025
|
PRIMARY | |||
|
4SMU15RR44
Created by
admin on Mon Mar 31 22:29:42 GMT 2025 , Edited by admin on Mon Mar 31 22:29:42 GMT 2025
|
PRIMARY | |||
|
99516
Created by
admin on Mon Mar 31 22:29:42 GMT 2025 , Edited by admin on Mon Mar 31 22:29:42 GMT 2025
|
PRIMARY | |||
|
93754
Created by
admin on Mon Mar 31 22:29:42 GMT 2025 , Edited by admin on Mon Mar 31 22:29:42 GMT 2025
|
PRIMARY | |||
|
m10861
Created by
admin on Mon Mar 31 22:29:42 GMT 2025 , Edited by admin on Mon Mar 31 22:29:42 GMT 2025
|
PRIMARY | Merck Index | ||
|
77-60-1
Created by
admin on Mon Mar 31 22:29:42 GMT 2025 , Edited by admin on Mon Mar 31 22:29:42 GMT 2025
|
PRIMARY |